Hepatocellular carcinoma is the liver malignancy that develops in the patients suffering from cirrhosis and chronic liver diseases. The disease is caused by liver diseases including hepatitis B or hepatitis C, cirrhosis, alcohol abuse, obesity, diabetes, iron storage disease and aflatoxin. Some of the common symptoms of hepatocellular carcinoma include, pain, lump in upper belly, bloating, weight loss, loss of appetite, nausea, fatigue and fever are the. According to American Cancer Society, around 40,710 new cases of primary liver cancer and intrahepatic bile duct cancer are expected to be diagnosed in the U.S., in 2017. Hepatocellular carcinoma is also a leading cause of cancer deaths worldwide, accounting for more than 600,000 deaths each year. Celgene Corporation is in the process of developing CC-122 as a signal transduction pathway modulator for the treatment of hepatocellular carcinoma. Some of the companies having a pipeline of hepatocellular carcinoma include Eisai Co., Ltd., Celgene Corporation, and AstraZeneca plc.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities, including information about clinical results, designations, collaborations, licencing, grants, technology and others.